Tirzepatide Pharmacokinetics Precisely Characterized Across Varying Degrees of Hepatic Impairment
A Study of Tirzepatide in Participants With Impaired Liver Function
Study Design
Population
32 participants with normal to severe hepatic impairment.
Intervention
Tirzepatide 5 mg SC, single dose.
Outcome
Tirzepatide pharmacokinetics.
Abstract
A completed Phase 1 study characterized tirzepatide pharmacokinetics in 32 participants with normal to severe hepatic impairment after a single 5 mg SC dose.